-+ 0.00%
-+ 0.00%
-+ 0.00%

Revvity Expands Automation Platforms At SLAS2026 As Investors Weigh Long Term Upside

Simply Wall St·02/10/2026 16:31:06
Listen to the news
  • Revvity (NYSE:RVTY) introduced several new discovery and automation platforms at SLAS2026.
  • The company showcased the Opera Phenix OptIQ high content screening system, EnVision Nexus One plate reader, and AssayMate workstation.
  • Revvity also highlighted collaborations around automated next generation sequencing workflows at the event.

Revvity, which focuses on life science tools and diagnostics, is pushing deeper into high throughput drug discovery and lab automation with these SLAS2026 launches. For investors, the new systems and workstations relate directly to demand from pharma, biotech, and academic labs that are looking to speed up experiments and reduce manual steps. The emphasis on automation aligns with interest in more efficient and reproducible research workflows.

The attention on automated next generation sequencing workflows indicates that Revvity is aiming to be closely involved in how labs handle sequencing workloads. As adoption of these platforms develops, investors may monitor how the company positions its broader portfolio around software, instruments, and services tied to automation ready labs.

Stay updated on the most important news stories for Revvity by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Revvity.

NYSE:RVTY Earnings & Revenue Growth as at Feb 2026
NYSE:RVTY Earnings & Revenue Growth as at Feb 2026

How Revvity stacks up against its biggest competitors

For Revvity, the SLAS2026 launches tighten its focus on high throughput screening and automation, areas where large pharma and biotech customers are already spending heavily with peers such as Thermo Fisher and Danaher. Higher sensitivity imaging, streamlined plate reading and a compact liquid handler that targets labs of any size all speak to workflows that can drive recurring reagent and software usage if adoption broadens across discovery programs.

How This Fits Into The Revvity Narrative

The new platforms align with both bullish and bearish narratives that center on automation and software as key levers for Revvity. Supporters of the bullish view may see these tools as reinforcing the company’s position in genomics and lab automation. The more cautious narrative focuses on whether product depth and pricing power are enough to offset regulatory pressure, weak funding pockets and exposure to biopharma and diagnostics budgets.

Risks and Rewards Investors Should Weigh

  • Expanding automation ready workflows in screening and next generation sequencing could deepen relationships with pharma and biotech customers and support higher quality recurring revenue.
  • Collaboration with New England Biolabs on automated NGS workflows positions Revvity alongside well regarded reagent providers, potentially improving its visibility in sequencing heavy labs.
  • Analysts have flagged regulatory and reimbursement risks in diagnostics and softer instrument demand, which could limit how much these launches translate into overall earnings growth.
  • Competition from large tool providers such as Thermo Fisher, Danaher and others may pressure pricing or slow adoption if rival systems are already embedded in key accounts.

What To Watch Next

From here, it is worth watching how quickly these systems are integrated into customer workflows, any commentary on order trends in earnings updates, and whether collaborations like the one with New England Biolabs expand into broader software or services deals. If you want to see how different investors are thinking about these moving parts, take a look at the community narratives for Revvity on this dedicated page and compare the bullish and bearish cases against your own expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.